Evidence map›Paper›PMID 33694021›Full record

ArticleActa neuropathologica2021

Age-associated insolubility of parkin in human midbrain is linked to redox balance and sequestration of reactive dopamine metabolites.

Jacqueline M Tokarew, Daniel N El-Kodsi, Nathalie A Lengacher, Travis K Fehr, Angela P Nguyen, Bojan Shutinoski, Brian O'Nuallain, Ming Jin, Jasmine M Khan, Andy C H Ng and 28 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 58 citations in OpenAlex.

  1. Review
  2. Species-dependent activities of the PINK1-parkin axis.Translational neurodegeneration · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Activation of parkin by a molecular glue.Nature communications · 2024
    Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. History of Parkinson's Disease-Associated Gene,International journal of molecular sciences · 2023
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors at 12 institutions in 6 countries.

Jacqueline M Tokarew *Program in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Daniel N El-Kodsi *Program in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Nathalie A LengacherProgram in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Travis K FehrProgram in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Angela P NguyenProgram in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Bojan ShutinoskiProgram in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Brian O'NuallainBioLegend Inc., Dedham, MA, USA.
Ming JinBioLegend Inc., Dedham, MA, USA.
Jasmine M KhanProgram in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Andy C H NgProgram in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Juan LiProgram in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Qiubo JiangProgram in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Mei ZhangDepartment of Pathology and Laboratory Medicine, The Ottawa Hospital, Ottawa, ON, Canada.
Liqun WangBioLegend Inc., Dedham, MA, USA.
Rajib SenguptaDepartment of Biochemistry, Karolinska Institute, Stockholm, Sweden.
Kathryn R BarberDepartment of Biochemistry, University of Western Ontario, London, ON, Canada.
An TranDepartment of Biochemistry, University of Western Ontario, London, ON, Canada.
Doo Soon ImDepartment of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.
Steve CallaghanDepartment of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.
David S ParkDepartment of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.
Stephanie ZandeeDepartment of Neuroscience, Faculty of Medicine, University of Montreal, Montreal, QC, Canada.
Xiajun DongAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA.
Clemens R ScherzerAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA.
Alexandre PratDepartment of Neuroscience, Faculty of Medicine, University of Montreal, Montreal, QC, Canada.
Eve C TsaiProgram in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Masashi TakanashiDepartment of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
Nobutaka HattoriDepartment of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
Jennifer A ChanDepartment of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada.
Luigi ZeccaInstitute of Biomedical Technologies, Italian National Research Council, Segrate, Milan, Italy.
Andrew B WestDepartment of Neurobiology, Duke University, Durham, NC, USA.
Arne HolmgrenDepartment of Biochemistry, Karolinska Institute, Stockholm, Sweden.
Lawrence PuenteProteomics Core Facility, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Gary S ShawDepartment of Biochemistry, University of Western Ontario, London, ON, Canada.
Gergely TothInstitute of Organic Chemistry, Research Center for Natural Sciences, Budapest, Hungary.
John M WoulfeProgram in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Peggy TaylorBioLegend Inc., Dedham, MA, USA.
Julianna J TomlinsonProgram in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada. jtomlinson@ohri.ca.
Michael G SchlossmacherProgram in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada. mschlossmacher@toh.ca.ORCID http://orcid.org/0000-0002-0394-0300
Ottawa Hospital · CAUniversity of Ottawa · CABioLegend (United States) · USWestern University · CABrigham and Women's Hospital · USJuntendo University · JPKarolinska Institutet · SEUniversité de Montréal · CADuke University · USInstitute of Biomedical Technologies · ITInstitute of Organic Chemistry · HUUniversity of Calgary · CA

Funding

Project 3: LRRK2 mediated macrophage responses in PDP50NS108675 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI STANDAERT, DAVID G. · 2018 to 2022
$9.9M
Mechanisms of LRRK2 Mediated NeurotoxicityR01NS064934 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WEST, ANDREW B · 2010 to 2025
$6.3M
Genome-Wide Prediction of Dementia in Parkinson's DiseaseR01NS115144 · NINDS · YALE UNIVERSITY · PI SCHERZER, CLEMENS R · 2019 to 2025
$4.4M
CIHRNINDS NIH HHS P50 NS108675NINDS NIH HHS R01 NS064934NINDS NIH HHS R01 NS115144
6 · The paper itself

Abstract

The mechanisms by which parkin protects the adult human brain from Parkinson disease remain incompletely understood. We hypothesized that parkin cysteines participate in redox reactions and that these are reflected in its posttranslational modifications. We found that in post mortem human brain, including in the Substantia nigra, parkin is largely insoluble after age 40 years; this transition is linked to its oxidation, such as at residues Cys95 and Cys253. In mice, oxidative stress induces posttranslational modifications of parkin cysteines that lower its solubility in vivo. Similarly, oxidation of recombinant parkin by hydrogen peroxide (H

Indexed as

AdolescentAdultAgedAged, 80 and overAgingAnimalsChildChild, PreschoolDopamineFemaleHumansMaleMesencephalonMiceMice, Inbred C57BLMiddle AgedDopamineparkin proteinUbiquitin-Protein LigasesAnti-oxidantDopamine metabolismNeuromelaninParkinParkinsonismPRKN/PARK2 geneRedox chemistryYoung-onset Parkinson disease

Identifiers

PMID33694021
PMCPMC8043881
OpenAlexW3133502202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.